Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. - Wikidata - wikimedia - TriplyDB

Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

http://www.wikidata.org/entity/Q33396140

about

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant.Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of an delta inulin adjuvanted recombinant pandemic influenza vaccine.Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions.Gamma ray sterilization of delta inulin adjuvant particles (Advax™) makes minor, partly reversible structural changes without affecting adjuvant activity.A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.Adjuvant activity of Sargassum pallidum polysaccharides against combined Newcastle disease, infectious bronchitis and avian influenza inactivated vaccines.A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules.An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.Immunomodulatory Activity and Protective Effects of Polysaccharide from Eupatorium adenophorum Leaf Extract on Highly Pathogenic H5N1 Influenza Infection Electrophoresis-enhanced detection of deoxyribonucleic acids on a membrane-based lateral flow strip using avian influenza H5 genetic sequence as the model.Application and use of Inulin as a tool for therapeutic drug delivery.Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection.DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant.Vaccine adjuvant safety: the elephant in the room.Nasal delivery of H5N1 avian influenza vaccine formulated with GenJet™ or in vivo-jetPEI® induces enhanced serological, cellular and protective immune responses.

P2860

Q30201987-0EE1D0E7-2461-40D0-B1AE-3AD76F8F8BBF Q30376743-F2D4FDA9-483A-44D0-B8A1-0D756925AF08 Q30377381-03F0178B-8BC7-4DDF-A105-2BBA8BD83B79 Q30379559-A7376DD2-D06D-498A-921F-2FA9CBA39E45 Q30389743-7C915B86-FFE1-447C-A905-E38C603F84CE Q30399988-C9752267-275C-402B-BA63-9FAD1C42BD87 Q30418297-A06264E2-A585-4000-80D0-8E081BB8901A Q30655287-2E4CE88E-C48F-4534-8674-D213D99ED741 Q33718615-8AC7D55B-4862-47DD-B14D-86F2638B5B0B Q33940730-5BE71565-8908-43C2-AD91-617786710285 Q34621859-239280D0-97E5-4C11-9E12-F4076A97AC20 Q35111000-22821EA6-80C4-4017-BEE3-00E59F5649CD Q36106655-EEE62765-3D21-4B8C-B3A7-EE9C29348FF9 Q36482325-307D16EB-478F-493E-8165-44DE80FCD667 Q36711264-55562ED0-1CA4-4BEF-A275-DD543B0F09D9 Q37057272-6EB32F10-F729-4453-ADAB-D6C01CF3A965 Q37123147-89A2EBCA-5B39-41B0-A319-7450F0810ED8 Q37197103-0C81C316-3D92-4FE2-B8AA-472BDC15A753 Q37212641-66B4F4E0-0E15-494F-8828-7789392E7A31 Q37731014-DFB5C3B3-01E9-4E36-B3B5-955EB8265315 Q38012147-06778B9F-7BB2-4D60-BBA1-5DBE0114DCCE Q40089069-F90DA8E7-385F-4DBE-BE7E-F9F6944442A5 Q40101584-E1D542DB-6B80-4288-88A8-03E5B38DF711 Q40715781-17C3C320-FB89-47B2-9411-0919C9F6F42F Q44538019-04549601-1B9A-4EEB-A4D7-3370D6AD944C Q52726414-37527EF9-6791-48ED-8888-913C06382D85

P2860

Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

http://www.wikidata.org/entity/Q33396140

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@ast

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@en

type

label

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@ast

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@en

prefLabel

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@ast

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@en

P1433

Q33396140-1EE50130-4614-418C-B0FA-35DE54443D41

P1476

Q33396140-7E7B6DAA-ECD8-4FA3-B9F0-5ABCC4C814E2

P2093

Q33396140-402EA4E7-485D-4A02-B10E-FB13560DFBD2

Q33396140-7CB66148-E9D1-4B1F-9F08-CC473DCE8F4E

Q33396140-7F170B58-5FF0-491F-AD07-EAA6568F956B

Q33396140-A8440026-ADE4-4B8E-9199-C1C10182CFB7

Q33396140-B744D947-5C3D-4DD5-9803-ECEE9AACAC33

Q33396140-C66FD81B-2157-4694-AB5F-C331154903F0

Q33396140-D622593E-F308-40C2-A01A-9DEB7D6C41D2

Q33396140-F305BE12-43BE-42A5-8AEB-6AA38C59E508

P2860

Q33396140-01CB8F73-A43C-4F44-8026-56870EC28475

Q33396140-0ED179F7-4154-424F-9E4A-436ECB59AA23

Q33396140-21755643-9F36-4FA9-87C5-1B345C9D8833

Q33396140-276FDBD3-8B02-455B-9F8F-6333880A66AD

Q33396140-296C2B32-B10C-46E9-AA9E-4BE0EFEC686F

Q33396140-3AF0FA16-CC57-487B-B77F-FEEA051CABB6

Q33396140-3BEEB69F-2A2E-4EA1-B63E-CB83B28CA319

Q33396140-40922825-67B3-4042-A6AB-76938EAA3942

Q33396140-41D378FA-6534-44E1-9987-C27B13699813

Q33396140-456ABDEC-C4EB-435F-ADB5-973EC27E0FB0

P304

Q33396140-A117B808-B916-4BAF-83B4-0BF4D87CFEEE

P31

Q33396140-5DB87BBC-76B5-4EBF-9AC0-41870D4B923D

P356

Q33396140-0CD2AD58-3A49-4325-9EEC-3E138FAADCB9

P407

Q33396140-1F734322-6247-45CC-A6C6-0259C76D51BF

P433

Q33396140-2F1DD882-BC4E-4162-B790-ED754E317BCB

P478

Q33396140-1D697659-7D7A-43D8-B959-7579E46D114B

P50

Q33396140-4B47A9FA-902A-4990-8720-40E2EEBCE345

Q33396140-C482F6D4-57A6-4EB8-BB61-6268C86FB8F7

P577

Q33396140-4EAC135E-0BDD-4413-9312-0944B93AD6D0

P5875

Q33396140-7D56DBA3-F182-4819-8228-C38B706C5655

P698

Q33396140-8F384A3A-A114-42F5-9CAF-1B78C5B88F0C

P921

Q33396140-1AAD4693-628E-4F98-9CC5-63C6C5223F9E

P932

Q33396140-3DE04932-0F6F-44BA-92DF-001CADCD99E2

P356

J.VACCINE.2011.06.078

P1433

P1476

Delta inulin polysaccharide ad ...... t lethal challenge in ferrets.

@en

P2093

Andrew P Gigliotti

http://www.w3.org/2001/XMLSchema#string

Frederick Koster

http://www.w3.org/2001/XMLSchema#string

Jennifer Knight

http://www.w3.org/2001/XMLSchema#string

John Pyles

http://www.w3.org/2001/XMLSchema#string

Nathaniel Donart

http://www.w3.org/2001/XMLSchema#string

Peng Gao

http://www.w3.org/2001/XMLSchema#string

R Colby Layton

http://www.w3.org/2001/XMLSchema#string

Zemmie Pollock

http://www.w3.org/2001/XMLSchema#string

P2860

Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model

Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret

Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.

Scientific barriers to developing vaccines against avian influenza viruses.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

P304

6242-6251

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2011.06.078

http://www.w3.org/2001/XMLSchema#string

P407

P433

37

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Nikolai Petrovsky

P577

2011-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51474713

http://www.w3.org/2001/XMLSchema#string

P698

21736913

http://www.w3.org/2001/XMLSchema#string

P921

polysaccharides

P932

3156374

http://www.w3.org/2001/XMLSchema#string